The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials

World Journal of Surgical Oncology

Research

Xiangyuan Li¹  Jianjian Zhang²  Yang Wang³  Dongying Wang⁴  Matao Zheng⁵  Yujie Chen⁵  Tongmin Huang⁵  Yetan Shi⁵  Yujing He⁵  Mengfei Wei⁵ 

[1] Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China;Department of Gastroenterology, Linhai Second People’s Hospital, 198 Dubei Road, 317016, Linhai, Taizhou, Zhejiang, China;Department of Pathology, Linhai Second People’s Hospital, Taizhou, Zhejiang, China;The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China;The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China;

关键词: Anti-epidermal growth factor receptor (anti-EGFR) target agent;    Cetuximab;    Panitumumab;    Conversion therapy;    Colorectal cancer;    Colorectal cancer metastases;   

DOI  :  10.1186/s12957-023-03222-3

 received in 2023-06-21, accepted in 2023-10-14,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundAdding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic colorectal cancer (mCRC). This study aims to analyze the efficacy and safety of additional anti-EGFR target agents.MethodsA systematic search was conducted on PubMed, Web of Science, Embase, and Cochrane Library. And all relevant studies published in English before January 2023 were collected to explore the impact of additional anti-EGFR targeted agent on the efficacy and safety of patients with potentially resectable mCRC (PROSPERO: CRD42022340523, https://www.crd.york.ac.uk/PROSPERO/).ResultsThis study included a total of 8 articles, including 2618 patients. The overall response rate (ORR) and R0 resection rates of the experimental group were higher than those of the control group, while there was no significant difference in progression-free survival (PFS) and overall survival (OS) between the two groups. In RAS/KRAS wild-type patients, the ORR (RR: 1.20, 95% Cl: 1.02–1.41, p = 0.03), R0 resection rate (RR: 1.60, 95% Cl: 1.17–2.20, p = 0.003), PFS (HR: 0.80, 95% Cl: 0.68–0.93, p = 0.003), and OS (HR: 0.87, 95% Cl: 0.76–0.99, p = 0.031) of the experimental group were higher than those of the control group. While in KRAS mutant patients, there was no statistical difference between the two groups in ORR, R0 resection rate, PFS, and OS.ConclusionThe addition of anti-EGFR targeted agents can improve the prognosis of RAS/KRAS wild-type patients with potentially resectable mCRC, while KRAS mutant patients may not benefit. In addition, the overall safety factor was controllable.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

12951_2015_155_Article_IEq47.gif

Fig. 4

Fig. 3

Fig. 2

Fig. 4

Fig. 1

Fig. 2

Fig. 3

Fig. 6

12936_2017_2075_Article_IEq45.gif

Fig. 1